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The most challenging task in colorectal cancer research nowadays is to understand the development of
acquired resistance to anti-EGFR drugs. The key reason for this problem is the KRAS mutations
appearance after the treatment with monoclonal antibodies (moAb). Here we present a mathematical
model for the analysis of KRAS mutations behavior in colorectal cancer with respect to moAb treatments.
To evaluate the drug performance we have developed equations for two types of tumors cells, KRAS
mutated and KRAS wild-type. Both tumor cell populations were treated with a combination of moAb and
chemotherapy drugs. It was observed that even the minimal initial concentration of KRAS mutation
before the treatment has the ability to make the tumor refractory to the treatment. Minor population of
KRAS mutations has strong inﬂuence on large number of wild-type cells as well rendering them resistant
to chemotherapy. Patient's immune responses are speciﬁcally taken into considerations and it is found
that, in case of KRAS mutations, the immune strength does not affect medication efﬁcacy. Finally,
cetuximab (moAb) and irinotecan (chemotherapy) drugs are analyzed as ﬁrst-line treatment of colorectal
cancer with few KRAS mutated cells. Results show that this combined treatment could be only effective
for patients with high immune strengths and it should not be recommended as ﬁrst-line therapy for
patients with moderate immune strengths or weak immune systems because of a potential risk of
relapse, with KRAS mutant cells acquired resistance involved with them.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The World Health Organization (WHO) declared colorectal
cancer (CRC) as the second most common cause of cancer mor-
tality in Europe (http://www.euro.who.int/en/health-topics/non-
communicable-diseases/cancer/news/news/2012/2/early-detec-
tion-of-common-cancers/colorectal-cancer). Monoclonal antibodyLtd. This is an open access article u
University of Pisa, Largo B.
08.(moAb) has been introduced as the most promising treatment to
ﬁght disease. The development of acquired resistance to the moAb
drug, due to KRAS mutations, makes the problem very complex in
terms of personalized treatment. We have developed a system of
non-linear ordinary differential equations (ODEs) to model the
impact of KRAS mutations on the moAb and chemotherapy com-
bination treatment of colorectal cancer. We have studied the
behavior of moAb and chemotherapy with respect to patient
immune responses and we have explored one moAb drug as a
potential candidate for ﬁrst-line therapy of CRC, in combination
with chemotherapeutic drug.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Monoclonal antibodies are a major breakthrough in CRC ther-
apeutic research because of their anti-EGFR activity (Deschool-
meester et al., 2010; Repetto et al., 2005). The Food and Drug
Administration (FDA) approved moAb drugs for colorectal cancer
including cetuximab and panitumumab (Gschwind et al., 2004).
These drugs produce promising results when administered in
combination with chemotherapeutic drugs (Van Cutsem et al.,
2007; Martinelli et al., 2009). They kill tumor cells in three ways:
by directly blocking the EGFR pathway, by enhancing the activity
of chemotherapeutic drugs and by enabling antibody-dependent
cellular cytotoxicity (ADCC) from natural killer cells.
The most relevant hypothesis concerning the CRC progression
during the moAb therapy is the selection of the treatment of KRAS
mutated cells. In particular, it is retained that there is a small
fraction of KRAS mutated cells in to the majority of wild-type CRC
cells, that will be selected by the moAb therapy while they will not
be killed from the treatment and they will survive, given treat-
ment acquired resistance (Tougeron et al., 2013). It has been fre-
quently reported that patients having KRAS mutations show no
signiﬁcant response to moAb treatment (Parsons and Meng, 2009;
Bando et al., 2011). KRAS mutations are found in approximately
35–45% of CRCs (Karapetis et al., 2008; Amado et al., 2008; Van
Cutsem et al., 2009). For this reason KRAS mutational status is
considered as predictive marker for determining the efﬁcacy of
anti-EGFR therapies, and KRAS screening tests are prescribed by
physicians before the start of treatments (Fakih, 2010). Only
patients having wild type KRAS are eligible for moAb therapy (De
Roock et al., 2008). Interestingly, some patients who have initially
only KRAS wild type cells before treatment, still remain irre-
sponsive to the medication because of the emergence of KRAS
mutations.
1.2. Previous models
Various colorectal cancer mathematical models have been
developed for basic tumor cell populations, cell proliferation and
for the more complex pharmacodynamic and pharmacokinetics in
colorectal cancer treatment (Ballesta and Clairambault, 2014).
These include models of colon crypts (van Leeuwen et al., 2006;
Fletcher et al., 2012; Murray et al., 2011; Johnston et al., 2007) and
models of chemotherapy for colorectal cancer (Monro and Gaffney,
2009; Boston and Gaffney, 2011). Recently, DePillis et al. proposed
a model which includes both chemo and immunotherapy along
with considerations of patient speciﬁc immunity parameters. This
is a comprehensive model which includes tumor cell and immune
cell populations, chemotherapy and monoclonal antibody treat-
ment. Results show the effect of drugs on chemorefractory tumors
(de Pillis et al., 2014).
The hypothesis of drug resistance of KRAS mutations in color-
ectal cancer is quite recent. Diaz et al. (2012) recently published a
paper in which they proved that pre-existed small number of
KRAS mutated cells are responsible for developing resistance to
panitumumab, a monoclonal antibody drug. Another very recent
paper by Stites (2014) describes a mathematical model which
evaluates how different KRAS mutated polymorphisms show dif-
ferent sensitivity to the EGFR inhibitors.
This paper is the extended version of our previous study in
which we explored the impact of KRAS mutations on the moAb
treatment by a mathematical model (Sameen et al., 2015). In the
current paper we have discussed our previous model in detail
along with further experiments and explanations about the
interplay between wild-type and mutated KRAS cells in the pre-
sence of monoclonal antibody drug and their impact on che-
motherapeutic effectiveness.2. Extending DePillis' model
The purpose of our model is to monitor tumor growth with
respect to KRAS mutational status during and after the moAb
therapy. Our model is an extension of the model developed by de
Pillis et al. (2014). We extend DePillis' model by representing
tumor cell populations using two equations, Eq. (1) for tumor cells
with wild type KRAS and Eq. (2) for mutant KRAS tumor cells. All
the other equations for natural killer (NK) cells, cytotoxic T lym-
phocytes (CTL), lymphocytes excluding NK cells and CTLs and
medications are as in the original model by de Pillis et al. (2014).
The model is implemented using the OCTAVE programming
environment (http://www.gnu.org/software/octave/; Eaton et al.,
2009). For detailed information and parameter values of the model
see the paper by de Pillis et al. (2015). The model includes equa-
tions for:
1. wild type tumor cell (Tw) and mutant tumor cell (Tm)
populations;
2. patient immune system including, natural killer cells (N), CD8þ
T-cells (L), lymphocytes (C) and interleukins (I);
3. chemotherapy (M) and monoclonal antibody (A) treatment;
4. patient immune strength (D).
We illustrate these four groups of equations in Sections 2.1.1–2.4
2.1. Equations for tumor cells
2.1.1. Equation for KRAS wild-type tumor cells
Tumor cells with KRAS wild-type nature go through natural
clonal expansion process to form a tumor mass. The only two
factors that interrupt the logistic growth of tumor cells are
immune system and therapy. This fact is modeled in the following
equation:
dTw
dt
¼ aTwð1bðTwþTmÞÞ cþξ
A
h1þA
 
NTwDTw
ðKtþKatAÞ
Tw
αTmþTw
ð1eδTMÞTwψATw ð1Þ
Logistic tumor growth is modeled by term aTwð1bðTwþTmÞÞ. The
innate immune system of the body ﬁghts tumor cells with the help
of natural killer cells (term cNTw) and CD8þ T cells (term
DTw). Two other ways by which tumor cells experience death
are chemotherapy (term Kt TwαTmþTwð1eδTMÞTw) and monoclonal
antibody treatment. The triple action of monoclonal antibody,
which is valid only for KRAS wild-type tumor cells, includes terms
for:
 direct killing ðψATwÞ;
 killing by enhancement of chemotherapy KatA TwαTmþTw

ð1eδTMÞTw

;
 killing by assisting natural killer cells ξ Ah1þANTw
 
.
2.1.2. Equation for KRAS mutant tumor cells
KRAS mutant cells behave differently from the KRAS wild-types
by disturbing the triple action behavior of monoclonal antibody
treatment. The monoclonal antibody is not able to directly kill
KRAS mutant tumor cells and also fails to create chemosensitiza-
tion in KRAS mutants. This fact is modeled in the following
equation:
dTm
dt
¼ aTmð1bðTwþTmÞÞ cþξ
A
h1þA
 
NTmDTm
 Kt
Tw
αTmþTw
 
1eδTM
 
Tm ð2Þ
Thus Eq. (2) is obtained from Eq. (1) by removing the two terms for
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and moAb-induced tumor death by enhancing activity of
chemotherapy.
Both of the equations for tumor contain the terms which
describe the interaction of moAb therapy with natural killer cells
or chemotherapy and their effect on tumor growth. The
enhancement of natural killer cells activity induced by moAb
therapy is the same for both mutated and wild-type cells. This is
represented in both equations by the ξ Ah1þANTw term. Che-
motherapy has reduced effectiveness against tumor cells during
monoclonal antibody treatment because of mutant cells. This is
represented in the model by Kt TwαðTmÞþTw. The chemotherapy
effectiveness decreases with the increase of the number of
mutated cells. This term is introduced in both the equations of
wild-type and mutant tumour cells for controlling the rate of
chemotherapy induced tumor death. Kt is the maximum rate of
chemotherapy induced tumor death in the absence of KRAS
mutant cells. The above term makes the effectiveness of the che-
motherapy dependent on the ratio of wild-type and total tumor
cells. This ratio is controlled by the parameter α in such a way that,
by increasing α, the rate of chemotherapy induced death is
decreased with respect to the increase in the mutant population.
Similarly, by increasing the initial number of KRAS mutated cells
or by decreasing the initial number of KRAS wild-type cells, the
rate of chemotherapy induced tumor death becomes much lower.
Hence, the function clearly models the phenomenon of che-
motherapy ineffectiveness, in conjunction with monoclonal anti-
body treatment, in case of presence of KRAS mutant cells.
Determining accurate α is the key task for producing realistic
results. α not only modulates the ratio of wild-type VS mutated
cells but it also depicts the inﬂuence of mutated cells on wild-type
cells in making them resistant to the chemotherapy as well. KRAS
mutated cells has the ability to render the neighboring wild-type
cells insensitive to the chemotherapy and the α determines the
range of mutated cell microenvironment.
2.2. Equations for immune response
Natural killer cells, CD8þ T-cells, other lymphocytes, and
interleukins all play a vital role in creating immediate immune
response with the initiation of tumor. Thus, in order to analyze the
effect of immune system response and strength on the tumor
proliferation we introduce four equations.
2.2.1. Natural killer cells
Natural killer (NK) cells are a fundamental part of host ﬁrst-line
defense system. Their activity is modeled in the following equa-
tion:
dN
dt
¼ eC fN pþpa
A
h1þA
 
NðTwþTmÞþ
pnNI
gnþ I
Knð1eδNMÞN
ð3Þ
They are produced from circulating lymphocytes (term eC) and
their activity is stimulated by interleukins (term pnNIgnþ I). NK turnover
is modeled by term fN. In case of tumor cells NK cells exhibit a
special killing mechanism known as “antibody-dependent cell-
mediated cytotoxicity” (ADCC). In this process NK cells recognize
tumor cells by special receptors that identify attached antibodies
on the surface of tumor cells. After recognition, NK cells release
some cytotoxic granules into the tumor cell which consequently
cause death. The cytotoxic granules are actually tumor killing
resources of NK cell; in case of exhaustion of these resources the
NK cells die (term pþpa Ah1 þA
 
NðTwþTmÞ). In addition, NK cells
may die due to chemotherapy toxicity (term Knð1eδNm ÞN).2.2.2. CD8þ T-cells
Cytotoxic lymphocytes are part of cell-mediated immunity.
They kill target cells by releasing into them specialized granules
that program them to undergo apoptosis. They are vital for killing
tumor cells. Their activity is modeled in the following equation:
dL
dt
¼ θmL
θþ Iþ j
TwþTm
kþðTwþTmÞ
LqLðTwþTmÞþðr1Nþr2CÞðTwþTmÞ
uL
2CI
κþ I Klð1e
δLMÞLþ piLI
giþ I
ð4Þ
CD8þ T cell turnover is modeled by term θmLθþ I and the breakdown
of their surplus in presence of of IL-2 is modeled by term uL
2CI
κþ I .
CD8þ T cells activity is stimulated by dead tumor cells, lysed by
themselves (term j Tw þTmkþðTw þTmÞL), NK cells (term r1NðTwþTmÞ) or the
general lymphocyte population (term r2CðTwþTmÞ). Interleukins
also perform stimulating effect on CD8þ T cells (term piLIgiþ I). CD8þ
T cell may die because of exhaustion of these tumor killing
resources (term qLðTwþTmÞ) or due to chemotherapy toxicity
(term Klð1eδLMÞL).
2.2.3. Lymphocytes
Lymphocyte count is the most important parameter to be
considered while modeling tumors undergoing chemotherapy.
Chemotherapy kills normal cells along with the tumor cells; hence,
patients are constantly checked for their lymphocyte count during
treatment. Reduction in lymphocyte count means weakening of
immune system, which makes the body more vulnerable. Lym-
phocyte activity is modeled in the following equation:
dC
dt
¼ αβCKcð1eδCMÞC ð5Þ
Lymphocytes are synthesized in the bone marrow (term α) and
their turnover is modeled by term βC. In addition, lymphocytes
may be killed by chemotherapeutic drugs (term Kcð1eδCMÞC).
2.2.4. Interleukins
Interleukin-2 is a major regulatory factor of immune responses.
It belongs to a immune signaling group of cytokines. Interleukin-2
works as an immune response system by increasing the activity
of cytotoxic T-cells. Their activity is modeled in the following
equation:
dI
dt
¼ μIþϕCþωLI
ςþ I ð6Þ
Interleukin-2 is produced in response to activated CD8þ T-cells
(term ωLIςþ I) or by naive CD8þT cells and CD4þT cells in the body
ðϕCÞ. Its turnover is modeled by term μI.
2.3. Equations for treatments
In order to monitor treatments, separate equations are deﬁned
for chemotherapy (irinotecan) and monoclonal antibody (cetux-
imab). Terms VMðtÞ and VAðtÞ, in Eqs. (7) and (8), respectively,
describe the amount of drug injected with respect to time.
2.3.1. Chemotherapy/irinotecan
The activity of chemotherapy depends on the concentration of
drug present in body at a speciﬁc time. This can be understood by
the rate of excretion of drug from body, which is modeled by term
γM. Chemotherapy using irinotecan is modeled by the following
equation:
dM
dt
¼ γMþVMðtÞ ð7Þ
Fig. 1. α value: 106 shows rapid decrease in wildtype and increase in mutant KRAS
cells (red: mutant and blue: wildtype). (For interpretation of the references to color
in this ﬁgure caption, the reader is referred to the web version of this paper.)
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Monoclonal antibodies bind to the epidermal growth factor
receptors (EGFRs) present on the surface of tumor cells. As an
average cell contains thousands of EGFRs, many molecules of
moAb drug are consumed in a single tumor cell. The loss of moAb
molecules due to their binding with the tumor (term
λðTwþTmÞ Ah2þA) is an important factor to be considered while
modeling moAb drug treatment to tumor. The rate of excretion of
drug from body is modeled by term ηA:
dA
dt
¼ ηAλðTwþTmÞ Ah2þA
þVAðtÞ ð8Þ
2.4. Patient immune strength formula
Immune strength, i.e. the effectiveness of CD8þ T-cells, is cal-
culated using Eq. (9). The formula uses the lymphocyte count L and
total tumor mass TwþTm along with other parameters to compute
immune strength.
D¼ d ðL=ðTwþTmÞÞ
l
sþðL=ðTwþTmÞÞl
ð9Þ
Immune strength D is calculated by considering the following
parameters:
d¼ immune strength coefficient;
l¼ immune system strength scaling coefficient;
s¼ value of ratio ðL=ðTwþTmÞÞl necessary for half maximal
CD8þ T  cell effectiveness against tumor:
ðIt tells how quickly CD8þ T  cells respond to the presence of
tumor:Þ
In our simulation we varied the parameters to generate three
types of immune strength values: strong, moderate and weak.
2.5. Initial conditions and drug dosages
The initial conditions for the model are taken from DePillis
model except the number of KRAS mutated cells. The initial
number of KRAS mutated cells, which can cause resistance to the
treatment, is not available in the literature. Thus we assumed a
small number for KRAS mutated cells, say 35, because even such a
small number of mutated cells is able to cause resistance. The
initial conditions for the model are as follows:
Tw¼ 4:65928 109
Tm¼ 35
N¼ 9 107
L¼ 1:8 105
C ¼ 9 108
M¼ 0
I¼ 1173
A¼ 0
The parameter values in our model are also taken from DePilis
except the rate of chemotherapy induced tumor death, which is
reduced to the minimum level because of KRAS mutations. As
DePillis, we assume that patients are already gone through ﬁrst-
line chemotherapy and are refractory to the treatment. Therefore,
the initial tumor is assumed to have a very large number of cells:
4:65928 109. If tumor size becomes less than 27 cells during the
treatment, it is assumed that the tumor is showing complete
response to the therapy. Similarly, tumors which remain largerthen 27 but do not continue to grow during the treatment are
considered to have partial response.
Treatment comprised individual or combination of monoclonal
antibody and chemotherapeutic drug, cetuximab and irniotecan,
respectively. The drugs are administered according to standard
FDA approved dosages and timings. For irinotecan, a 125 mg/m2
dose is given over 90 min once a week, for 4 weeks. For cetuximab,
a loading dose of 400 mg/m2 is administered for 2 h, followed by a
250 mg/m2 dose over 60 min given every week for one month.3. Results
3.1. Monoclonal antibody effect on chemotherapy
As described before, the effectiveness of chemotherapy against
tumor cells gradually reduce during monoclonal antibody therapy
due to KRAS mutated cells. This gradual ineffectiveness with the
increase of mutated cells is modulated by term α in the model. We
have explored all of the possible α values ranging from 10 to 109.
Initially we have started from very low range of α but our results
contradict with the reported experimental data. The α value is
then raised up to α¼ 106 or α¼ 107 to get the actual results
(Figs. 1 and 2). The reason for this much high α is that a single
KRAS mutated cell has the tendency to inﬂuence thousands of
wild-type cells.
We have also analyzed our results by varying α values along
with the varying initial number of mutated cells. Lower the α
greater is the impact of chemotherapy but with the increase in
number of mutated cell this effect is not much signiﬁcant. But with
lower α and small number of mutated cells the drug has profound
effect, which is not an actual phenomenon. In reality, che-
motherapy also tend to become ineffective with the passage
of time.
In our simulations we used the value α¼ 107 because this
shows a gradual decrease in the efﬁciency of the chemotherapy as
compared to a too rapid reduction experimented with the smaller
value α¼ 106.
Fig. 2. α: 107 shows gradual decrease in wildtype and increase in mutant KRAS
cells (red: mutant and blue: wildtype). (For interpretation of the references to color
in this ﬁgure caption, the reader is referred to the web version of this paper.)
Fig. 3. Irinotecan monotherapy (red: mutant and blue: wildtype). (For interpreta-
tion of the references to color in this ﬁgure caption, the reader is referred to the
web version of this paper.)
Fig. 4. Cetuximab monotherapy (red: mutant and blue: wildtype). (For inter-
pretation of the references to color in this ﬁgure caption, the reader is referred to
the web version of this paper.)
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tumors
Our model has been evaluated for standard treatments by
chemotherapy and monoclonal antibodies for tumors with KRAS
mutations. The KRAS mutated tumors are treated according to
standard dosage of drugs and are evaluated for both monotherapy
and combination therapy.
3.2.1. Cetuximab and irinotecan monotherapy
In accordance with the literature, in our model cetuximab
monotherapy has no impact on colorectal tumors because of the
number of elevated KRAS mutated tumor cells (Fig. 4). Similarly,
irinotecan monotherapy has no impact on the tumor because of
the chemorefractory status of tumor. Here, no increase in KRAS
mutated cells is noticed (Fig. 3). Results show that, although both
drugs fail as monotherapies, failure of cetuximab is speciﬁcally
caused by an increase in the number of KRAS mutated cells.
3.2.2. Cetuximab and irinotecan combination therapy
For patients presenting metastatic colorectal cancer, cetuximab
and irinotecan are recommended in combination. We used our
model to test the combination of the two drugs. This allowed us to
understand the impact of combined therapy on KRAS mutated
tumor cells (Fig. 5). KRAS mutated cells grow with the passage of
time and KRAS wild type cells start to reduce. However, as the
initial number of KRAS mutated cells is very small, their increase is
not clearly visible in the ﬁgure. Anyway, even this very low level of
KRAS mutated cells is still able to gradually reduce the activity of
drugs (Fig. 5). The combination therapy is only effective for KRAS
wild-type tumours (Fig. 6).
3.3. Patient responses to the therapy
We simulated our model for patients with different immune
strengths. Generally, it is believed that a strong immune system
both helps the medication and facilitates quick recovery, whilepatients with weak immunity do not respond well to the medi-
cine. We analyzed the interaction between patient immune
strength and treatment in case of mutation development during
and after medication. The hypothetical immune strength values
are calculated for generating weak, moderate and strong immune
responses. These values are generated by the formula for immune
strength (Eq. (9)) by changing the values of its parameters.
Our results are summarized in Table 1. Patients without KRAS
mutations have complete response (CR), partial response (PR) and
no response (NR) for strong, moderate and weak immunity,
respectively. With KRAS mutations the immune strength has no
signiﬁcant impact on the treatment. KRAS mutated tumours
Fig. 6. Cetuximab and irinotecan as combination therapy without KRAS mutant
(red: mutant and blue: wildtype). (For interpretation of the references to color in
this ﬁgure caption, the reader is referred to the web version of this paper.)
Table 1
Cetuximab and irinotecan combination therapy.
Immune strength With KRAS mutation Without KRAS mutation
Strong immunity NR/PR (Fig. 7) CR (Fig. 8)
Moderate immunity NR (Fig. 9) PR (Fig. 10)
Weak immunity NR (Fig. 11) NR (Fig. 12)
Fig. 7. Strong immunity response with KRAS mutation.
Fig. 8. Strong immunity response without KRAS mutation.
Fig. 5. Cetuximab and irinotecan as combination therapy with KRAS mutant (red:
mutant and blue: wildtype). (For interpretation of the references to color in this
ﬁgure caption, the reader is referred to the web version of this paper.)
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is a partial response in presence of a high immune strength. For
moderate and weak immunity there is no response at all.
3.4. Cetuximab and irinotecan as ﬁrst-line therapy
In this section we explore the possibility of using cetuximab
and irinotecan as ﬁrst-line therapy. Initial conditions are the same
as shown in Section 2.5. Patients having weak immunity do not
show any signiﬁcant response to the cetuximab and irinotecan as
ﬁrst-line therapy (Fig. 13). Tumor size reduces signiﬁcantly in
patients with moderate immunity, but the number of KRAS
mutated cells show a relevant increase (Fig. 14). The response to
Fig. 9. Moderate immunity response to KRAS mutation.
Fig. 10. Moderate immunity response without KRAS mutation.
Fig. 11. Weak immunity response with KRAS mutation.
Fig. 12. Weak immunity response without KRAS mutation.
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very low number of initial KRAS mutated cells (Fig. 15).4. Discussion
Emergence of KRAS mutated status is an alarming situation for
colorectal cancer patients being treated with anti-EGFRs. Presence
of KRAS mutations in a tumor treated with monoclonal antibodies
is a sign of becoming refractory to treatments. In order to under-
stand the phenomenon of developing resistance to the anti-EGFRs
we developed a mathematical model with separate equations for
KRAS mutant and wild-type cells.KRAS mutations are considered as driver of resistance to anti-
EGFR therapy in colorectal cancer. Subset of KRAS wild-type cells
in colorectal tumor initially responds very effectively to the anti-
EGFR drugs but the presence of traces of KRAS mutations prior to
treatment ultimately results in the development of acquired
resistance to the drug. Hence, the treatment of colorectal tumor
with anti-EGFRs is only recommended when the KRAS mutation
status is zero. The anti-EGFR treatments to colorectal tumors
containing minute quantity of KRAS mutated cells consequently
develop resistance to the therapy. The pre-existing subclones of
mutated cells multiply very rapidly during the treatment and on
the other hand KRAS wild-type cells reduce signiﬁcantly in their
number due to efﬁcient targeting procedure of monoclonal
Fig. 13. Cetuximab and irinotecan as ﬁrst-line therapy: weak immune response
(red: mutant and blue: wildtype). (For interpretation of the references to color in
this ﬁgure caption, the reader is referred to the web version of this paper.)
Fig. 14. Cetuximab and irinotecan as ﬁrst-line therapy: moderate immune response
(red: mutant and blue: wildtype). (For interpretation of the references to color in
this ﬁgure caption, the reader is referred to the web version of this paper.)
Fig. 15. Cetuximab and irinotecan as ﬁrst-line therapy: strong immune response
(red: mutant and blue: wildtype). (For interpretation of the references to color in
this ﬁgure caption, the reader is referred to the web version of this paper.)
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mutated cells and makes tumor much more refractory to other
treatments as well. So, the initial drop in the number of wild-type
cells does not contribute much in shrinking the overall size of the
tumor after the treatment. Diaz et al. was the ﬁrst to discover the
presence of small number of KRAS mutated cells in circulating
tumor DNA at very early stage of drug treatment. This indicates
that ostensibly looking KRAS wild-type tumors hide inside some
fatal KRAS mutated cells as well. The mathematical model by Diaz
et al. (2012) suggests that circulating DNA analysis for KRAS
mutation detection can act as a marker for early detection of
relapse of disease. Misale et al. (2012) also conﬁrmed the Diaz
et al. results by in vitro analysis and declared that the reason fordevelopment of resistance is the pre-existence of clones of KRAS
mutated cells.
A major problem in colorectal cancer is to identify the behavior
of monoclonal antibody therapy in presence of KRAS mutations
and the impact of the mutations on other therapies. More speci-
ﬁcally, exploring the sensitivity of monoclonal antibody drugs to
the chemotherapy and natural killer cells activity in the presence
of mutations is another key issue in understanding drug efﬁcacy
(Arnold and Seufferlein, 2010). We have speculated in our model
that in case of natural killer cells, cetuximab has equal enhancing
effect on both KRAS mutant and wild-type cells. In other words,
KRAS mutational status has no signiﬁcant impact on the antibody-
dependent cellular cytotoxicity (ADCC) mediated by the drug (Wu
et al., 2008).
The anti-EGFR drugs along with chemotherapy give promising
results for colorectal tumors with wild-type KRAS. Monoclonal
antibody is not only a perfect EGFR blocker but it also boosts the
activity of chemotherapeutic drug molecules and results in
enhancement of overall antitumor activity (Wong, 2005; Prewett
et al., 2002, 2007; Jonker et al., 2007; Saltz et al., 2004; Adams and
Louis, 2005). Hence, the monoclonal antibody therapy in combi-
nation with chemotherapy is proved to be effective in avoiding
relapses and increasing the progression free survival period in
colorectal cancer patients. The presence of KRAS mutation in col-
orectal tumor leaves this combination therapy with no profound
effects on tumor size this means that the chemosensitization
operation of moAb drugs does not imply on KRAS mutated tumor
cells (Tol et al., 2009). The wild-type KRAS tumors have longer
progression free survival as compared to mutated KRAS tumors
when treated with combination therapy (Lievre et al., 2008;
Bokemeyer et al., 2008; Van Cutsem et al., 2008). This reduced
survival period due to mutated KRAS cells is also conﬁrmed in our
experiments. The ineffectiveness of both cetuximab and irinotecan
drugs increases with increase in number of mutated cells as these
drugs only inﬂuence the wild-type cells. Cetuximab has been
frequently reported to increase chemotherapeutic activity upon
combination with irinotecan drug in tumor cells (Jonker et al.,
2007). Studies show that KRAS mutant cells do not allow cetux-
imab to produce such type of chemosensitization. Chemotherapy
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mutated cells are signiﬁcantly lower in numbers but when the
number of mutated cells in the tumor start to increase the sensi-
tivity of chemotherapy reduces gradually. In the initial phase of
treatment with combination therapy the drugs seems to reduce
tumor a little but soon it goes back to the much bigger and drug
refractory state. Time tumor takes to go back in to maximum or
more resistant state is the time between the relapse which is
signiﬁcantly lower in case of KRAS mutations.
Our results repeatedly conﬁrmed that small number of mutated
cells can have an inﬂuence on whole tumor for making it refrac-
tory to the therapies. The major point to ponder is that how a very
small proportion of mutated cells make the drug insensitive even
to the wild-type cells. The moAb drug effectiveness on the wild-
type cells is well explained but understanding the change in
behavior of wild-type cells because of growing number of mutated
cells during treatment is a challenging task for the researchers.
Parsons and Myers explained this myth of KRAS wild-type cells
behavior by blaming KRAS mutant cells responsible for every
unexplained resistance mechanism of the tumor. The mutated
cells undergo negative selection process in poly clonal tumors.
Parson and Myers suggested KRAS mutations as “transdriver
mutations”, these are the mutations which are able to speed up
the tumor progression process even if they are in small proportion
(Parsons and Myers, 2013b, 2013a).
The possible reasons for strong inﬂuence of small number of
mutated cells on wild-type cells for producing phenomenal
resistance against anti-EGFR drugs lies in tumor heterogeneity and
in the theory of cancer stem cells. Tumor heterogeneity is the
reason for failure of chemotherapy induced tumor cell death, not
only for mutated cells but also for wild-type cells when treated
along with the moAb drug (Vilar and Tabernero, 2012; Baldus
et al., 2010; Hasovits et al., 2013). In order to model this phe-
nomenon we have regulated the rate of chemotherapy induced
tumor death. We assumed that the effect of chemotherapy
decrease with the increase in KRAS mutated cells. Therefore, we
cannot take any beneﬁt from the chemosensitization activity of
moAb drugs in case of KRAS mutations. The chemotherapy may
work effectively only at the beginning of the treatment but then,
with the increase of KRAS mutant population, it starts to loose its
strength. Tumor heterogeneity explains the dispersal of mutated
cells in the tumor mass. These distributed resistant cells have
strong impact on their microenvironment (Junttila and de Sau-
vage, 2013). They perform like small radiators emitting some
harmful radiations which affect a range of surrounding cells,
leaving them resistant to the therapies irrespective of their origi-
nal wild-type status. Hobor et al., reported that wild-type KRAS
cells has the ability to grow during the cetuximab treatment when
KRAS mutated cells are present in the tumor. Resistant mutated
cells maintain micro-environment inside tumor by inﬂuencing
their neighboring cells rendering drug sensitive wild-type cells to
resistant cells. The KRAS mutated cells secrete increased amount
of ligands that has the ability to protect wild-type cells from EGFR
blockade by cetuximab drug. The secretion of TGF α and amphir-
egulin by moAb resistant KRAS mutated cells sustain the EGFR
signaling in wild-type cells too (Hobor et al., 2014).
Tumor heterogeneity is also the major reason for the failure of
initial KRAS mutation screening test. The incorrect assignment of
wild-type status to the tumor is because of widely dispersed
mutated cells inside the tumor. The test is only applied to a small
chunk of tumor and there is a chance that the block selected for
test may not contain KRAS mutation and hence give wrong result
(Richman et al., 2011; Baldus et al., 2010).
Tumor heterogeneity role in therapeutic resistance is irrefu-
table but the root cause of heterogeneity development is the
cancer stem cells (CSCs) (Marusyk et al., 2012; Shackleton et al.,2009). CSCs are best described as the cells having selective
advantage of proliferation over the other cells in the tumor. They
occur as minority in tumor and tend to have self renewing prop-
erty that drive tumorigenesis (Clarke et al., 2006; Dean et al.,
2005; Reya et al., 2001; Clevers, 2011). CSCs are rare cells with
potential of being naturally resistant to chemotherapy. The area of
CSC research is still underdeveloped that is why there is no con-
crete description about the process of chemotherapeutic drug
resistance due to CSCs. If we consider KRAS mutations as CSC then
failure of chemotherapy in our results is justiﬁed. KRAS mutated
cells are recently been explored as potential CSCs in colorectal
tumors. Evidences support the hypotheses of KRAS mutated cells
as CSCs, which gives us enough explanation about the acquired
resistance in colorectal tumor due to KRAS mutations (Fearon and
Wicha, 2014; Moon et al., 2014).
Patient immune responses play a vital role in oncotherapeutic
processes and this role varies from positive to negative with strong
to weak immune strength respectively. The immune strength
becomes unimportant for KRAS mutated patients because the
initially strong immunity turns into a weak one due to the
development of secondary KRAS mutations during the treatment
(Smakman et al., 2005). Even with the highest immune strength,
the response to the drugs is only partial (sometimes). In our
simulations tumor size was set to its maximum and it is con-
sidered refractory to the chemotherapy given as ﬁrst-line to the
patients. The reason for adopting these criteria is because cetux-
imab is generally given as third- or fourth-line treatment to the
patients as ﬁnal rescue (Pfeiffer et al., 2008; Vincenzi et al., 2006).
Hence it is proved that there is no correlation between immune
strength and combination treatment for KRAS mutated patients.
The cetuximab and irinotecan combination therapy is proved to
be very effective as ﬁrst-line therapy for colorectal cancer but this
is true only for KRAS wild-type patients (Folprecht et al., 2006;
Van Cutsem et al., 2009). Although KRAS screening tests are
always performed before starting monoclonal antibody treat-
ments, there is a risk of minimal quantities of KRAS mutated cells
that are not detected by common sequencing processes of
laboratories. In this case critical questions arise about the patient's
response to cetuximab and irinotecan as ﬁrst-line therapy. Our
results show complete response only in patients with strong
immunity. High immune strength means little number of KRAS
mutations, so there is a chance that the drug kills wild-type cells
quickly and chemotherapy also gets the chance to kill mutant cells.
The ﬁrst-line therapy seems to work also for moderately immune
persons but, at the same time, increases the KRAS mutation level,
which is a sign of recurrence of disease. Patient responses are also
dependent upon the initial KRAS mutant cell concentrations. If the
initial mutant level is very low then a complete response can be
obtained. However, in case of greater level of initial KRAS mutants,
the response is only partial with decrease in tumor size and sig-
niﬁcant increase in KRAS mutant levels, which doubles the chan-
ces of relapse. The relapse after cetuximab as ﬁrst-line therapy will
be more lethal because of acquired resistance to the drugs due to
increased KRAS mutant populations.5. Conclusion and future work
In cetuximab and irinotecan combination therapy the rapid
increase in levels of KRAS mutations and the partial or no response
on the tumor size an indications of the development of resistance
to the drugs. Using our model we could measure the level of KRAS
mutations that can be tolerated to avoid resistance to anti-EGFRs.
This could provide information to stop the anti-EGFR treatment
before reaching the threshold value for KRAS mutant cells. The
treatment could be switched from anti-EGFR to anti-KRAS drugs.
S. Sameen et al. / Journal of Theoretical Biology 389 (2016) 263–273272We do not know the clinical perspective about switching treat-
ments, but this could provide a better way to solve the secondary
KRAS mutation problem in colorectal cancers.
Patients with stronger immunity can be highly recommended
cetuximab and irinotecan as ﬁrst-line therapy but there is no
instrument to accurately judge a person's immunity. Thus there is
a potential risk associated with standard dosage cycles of drugs.
The failure of the treatment will ultimately lead towards tumor
progression with much higher rates. Moreover, the increased
number of KRAS mutations makes the problem even more com-
plex by creating resistance against the drugs. The co-occurrence of
EGFR and KRAS mutations in a colorectal cancer patient is indeed
the worst case scenario.
We want to further explore KRAS mutated cells fate as cancer
stem cells and development of tumor heterogeneity. Tumor het-
erogeneity makes the problem of resistance against the drugs even
worse as a small number of mutated cells is able to make drugs
ineffective even for a large number of wild-type cells. We plan to
further investigate this interplay between wild-type and mutant
cells caused by tumor heterogeneity.
As future work, we also aim to develop a stochastic computa-
tional model for KRAS mutations and combine it with the current
mathematical model in order to increase the accuracy of the
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